Comparator drug sourcing agreements, tracked from order to destruction

Comparator products are the quiet risk in many clinical supply plans. The investigational product is under the sponsor’s control. The comparator is someone else’s marketed drug, bought in the quantities, presentations and countries the protocol requires, often through specialized sourcing partners and sometimes during periods of constrained supply. The sourcing agreement is what turns that exposure into enforceable commitments. When it is vague, the sponsor carries risks it cannot price or control, from short-dated stock to undocumented handling.

Those commitments are detailed. A comparator lot is only useful if its remaining shelf life covers the dosing window, its documentation satisfies the regulators in each trial country and its storage history is unbroken. Price, quantity and delivery date matter, but a shipment that arrives on time with insufficient expiry or a missing certificate can still stall site activation. In multinational studies, each additional country adds its own documentation and import expectations, which multiplies the number of terms that must be right.

This datasheet is for clinical supply managers, sourcing leads and quality teams who buy comparators. It lists the terms that need tracking, the gaps that cause delays and how Aavenir turns sourcing agreements into obligations with owners, dates and evidence.

Terms every comparator sourcing agreement needs tracked

These are the provisions that most often decide whether a comparator supply plan holds. Each should exist as a structured field, not only as text in the agreement, so receipt checks and reporting can use it without someone rereading the contract.

• Minimum remaining shelf life, the expiry threshold at delivery, set so product remains usable through packaging, distribution and the dosing period.
• Lot documentation, certificates of analysis, batch release information, country of origin and any documents the importing regulator requires.
• Chain of custody and storage, requirements for traceable handling and temperature control from the manufacturer to the sponsor’s depot, with excursion reporting.
• Quantities and allocation, committed volumes, call-off schedules, single-lot requests and what happens when the supplier cannot meet demand.
• Returns and destruction, rules for unused, damaged or expired stock, including reconciliation counts and certificates of destruction.

Many of these terms depend on data that changes after signature. Protocol amendments shift quantities. New countries join the study and add documentation requirements. Manufacturers change packaging. A sourcing agreement that lives as a signed PDF cannot keep up, and the team ends up relying on email threads to remember what the supplier actually committed to. Quality teams already familiar with electronic record controls under 21 CFR Part 11 and GxP will recognize the need for versioned, auditable records of what was agreed and what was delivered.

How Aavenir supports comparator sourcing

Aavenir treats each sourcing agreement as a set of obligations linked to the study, the supplier and each delivery. These capabilities matter most to clinical supply teams.

• AI term extraction. Shelf life thresholds, documentation lists, allocation clauses and return rules are pulled from agreements and proposed for review, cutting abstraction time.
• Delivery-level evidence. Each shipment record carries lot numbers, expiry dates, certificates and temperature data, checked against the contract requirement.
• Supply risk alerts. Reminders fire ahead of call-off dates, allocation reviews and expiry thresholds so shortfalls surface before sites run low.
• Amendment control. Protocol-driven changes to quantities, countries or presentations are routed as amendments with approval history and version tracking.
• Audit-ready records. Approvals, changes and evidence are logged with users and timestamps, supporting inspection readiness for sponsors and partners.

Five steps to put comparator agreements under control

Step 1, Build a comparator term template

Define the standard fields every sourcing agreement must capture, from shelf life threshold to destruction rules. Use it for new agreements and as the target structure when abstracting existing ones, so every study reports on the same terms. Involve quality early, since they will rely on the same fields during receipt and release.

Step 2, Abstract active agreements

Load current sourcing agreements and use AI extraction to populate the template. Clinical supply and quality reviewers confirm each value, paying close attention to documentation lists and temperature requirements that vary by product.

Step 3, Link agreements to studies and lots

Connect each agreement to the protocols it supports and each delivery to the agreement. This gives one view of what was ordered, what arrived, what it cost and whether each lot met the contract. It also lets supply planners see at a glance which studies depend on a single supplier or a single lot.

Step 4, Automate checks at receipt

Compare delivered lot data against contract thresholds as shipments arrive. Flag short expiry, missing certificates or temperature excursions for quality review before product is released to packaging or distribution. Each flag becomes a task with an owner and a due date, so nothing waits in an inbox while sites wait for kits.

Step 5, Close out with reconciliation

At study end, track returns, destruction certificates and final quantity reconciliation as dated obligations. Archive the complete record so it is available for audits and future sourcing decisions on the same comparator. The next study that needs the same product starts with real supplier performance data instead of anecdotes.

Why comparator supply needs contract-level visibility

Clinical supply teams usually have strong forecasting and depot systems. What they often lack is a link between those systems and the commercial terms behind each comparator purchase. Without it, a short-dated lot may be accepted because nobody checked the contract threshold, a price change goes unnoticed or a supplier’s allocation commitment is never invoked during a shortage. Connecting agreements to studies and deliveries closes that gap. It also helps finance and procurement understand the true cost of comparator supply across a portfolio, including write-offs from expiry, and gives sourcing leads data for the next negotiation. Patterns become visible: which suppliers consistently deliver short-dated lots, which documentation gaps recur and which studies absorb the most unplanned purchases. The obligation-tracking model is the same one life sciences teams use for site contracts in the clinical trial agreement automation guide, so it fits alongside existing processes rather than replacing them.

Comparator sourcing terms and the evidence behind them

Use this table to check whether your agreements and receipt processes capture what quality and supply teams need. Exact requirements depend on the product, the trial countries and applicable regulations.

Comparator drug sourcing succeeds when commercial terms, quality requirements and delivery data line up. Put shelf life, documentation, custody, allocation and close-out terms into structured obligations, check every lot against them and keep the evidence. Aavenir gives clinical supply teams that control without adding another spreadsheet, and gives quality a clean record when an inspector asks how a comparator lot was qualified for use.

For related guidance, see Clinical supply depot agreements, tracked end to end, DSCSA trading partner agreement control datasheet and Clinical trial site payment terms: a tracking datasheet.

Aavenir Life Sciences & Pharma PracticeAavenir’s Life Sciences & Pharma practice works with clinical supply, quality and sourcing teams on GxP-ready contract and obligation management.